Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs

US12319916B2 · kind B2 · utility

Assignee

• CAMP4 Therapeutics Corporation · US

Inventors

• Alfica Sehgal · Cambridge, US
• Bryan J. Matthews · Somerville, US
• David Bumcrot · Belmont, US
• Justin Andrew Caravella · Cambridge, US
• Mario Esteban Contreras Gamboa · Cambridge, US
• Rachana S. Kelkar · Malden, US
• Yun Joon Jung · Lexington, US
• Yuting Liu · Lexington, US
• Rutuja Sudhakar Pai · Boston, US
• Subhadeep Roy · Boulder, US
• Yuchun Guo · Framingham, US

Key dates

• Filing date: Jun 24, 2024
• Grant date: Jun 3, 2025
• Expiry date: Jun 24, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Described herein are methods of modulating gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for modulating the levels of gene products, for example, increasing expression of Carbamoyl-Phosphatase Synthetase 1 (CPS1), thereby treating diseases associated with aberrant gene expression.